CN Stock MarketDetailed Quotes

688192 Dizal Pharmaceutical

Watchlist

43.82
+6.01+15.90%

Market Closed Sep 30 15:00 CST

18.21BMarket Cap-19415P/E (TTM)

Dizal Pharmaceutical Key Stats

Cash Flow

All

YOY

Hide blank lines

(Q6)Jun 30, 2024

(Q3)Mar 31, 2024

(FY)Dec 31, 2023

(Q9)Sep 30, 2023

(Q6)Jun 30, 2023

(Q3)Mar 31, 2023

(FY)Dec 31, 2022

(Q9)Sep 30, 2022

(Q6)Jun 30, 2022

(Q3)Mar 31, 2022

Assets

Current assets

Money funds

26.32%102.85M

11.76%95.31M

-39.02%74.2M

-46.99%69.4M

-52.42%81.42M

-63.79%85.28M

-66.59%121.67M

-46.42%130.91M

-50.48%171.13M

--235.54M

Transactional financial assets

-23.57%725.09M

-35.26%721.6M

-47.95%674M

-42.65%843.82M

-39.46%948.72M

-32.70%1.11B

-24.32%1.29B

--1.47B

--1.57B

--1.66B

Notes receivable and accounts receivable

--93.7M

--44.13M

--48.04M

--45.8M

----

--0

-Accounts receivable

--93.7M

--44.13M

--48.04M

--45.8M

----

--0

Other receivables (including interest and dividends)

-14.07%3.62M

1.53%3.4M

5.17%3.37M

14.00%3.73M

29.18%4.21M

7.42%3.35M

117.31%3.2M

119.09%3.27M

445.38%3.26M

--3.12M

-Accrued interest receivable

----

--357.87K

--266.05K

----

-Other receivable

-8.28%3.62M

----

5.17%3.37M

----

21.02%3.95M

----

117.31%3.2M

----

445.38%3.26M

----

Advance payment

-46.62%38.12M

-10.45%49.81M

25.49%53.14M

108.77%81.05M

115.98%71.41M

48.02%55.62M

50.71%42.35M

62.05%38.82M

48.21%33.06M

--37.58M

Inventories

145.83%32.61M

559.81%33.44M

363.04%23.47M

--20.09M

--13.27M

--5.07M

----

Other current assets

58.56%26M

363.12%31.23M

461.10%34.14M

--20.98M

--16.4M

--6.74M

--6.08M

----

Total current assets

-9.99%1.02B

-22.96%978.93M

-38.20%910.36M

-34.02%1.08B

-36.01%1.14B

-34.24%1.27B

-30.26%1.47B

491.88%1.64B

372.44%1.77B

--1.93B

Non Current assets

Fixed assets

-0.47%21.25M

----

79.09%22.1M

----

93.98%21.35M

----

-5.08%12.34M

----

-19.35%11.01M

----

Constru in process

401.75%76.51M

----

50.74%13.35M

----

73.13%15.25M

----

75.69%8.85M

----

--8.81M

----

Intangible assets

-6.15%446.29M

-6.10%454.19M

-6.11%461.98M

3.96%469.54M

3.43%475.54M

3.58%483.68M

3.61%492.02M

-6.37%451.66M

-6.25%459.75M

--466.98M

Long deferred expense

58.87%12.84M

101.99%15.1M

112.68%16.99M

20.94%10.78M

16.85%8.08M

50.10%7.48M

76.04%7.99M

250.01%8.91M

128.87%6.92M

--4.98M

Usufruct assets

-30.62%54.52M

-21.04%60.67M

-18.98%66.81M

-16.31%73.41M

-2.12%78.58M

-9.78%76.84M

-4.59%82.47M

-1.81%87.72M

-5.30%80.29M

--85.16M

Other non current assets

131.06%11.58M

-60.24%2.85M

-5.22%4.79M

-93.81%3.39M

-91.61%5.01M

-87.61%7.17M

-89.78%5.06M

7.70%54.81M

44.52%59.72M

--57.87M

Total non current assets

3.18%622.99M

-4.82%573.31M

-3.73%586.02M

-5.59%588.49M

-3.62%603.81M

-4.62%602.33M

-3.90%608.73M

-2.25%623.34M

-1.05%626.49M

--631.53M

Total assets

-5.42%1.64B

-17.13%1.55B

-28.12%1.5B

-26.21%1.67B

-27.56%1.74B

-26.95%1.87B

-24.18%2.08B

147.69%2.27B

138.01%2.4B

--2.56B

Liabilities

Current liabilities

Short term loan

154.97%203.08M

--264.55M

--200.11M

--199.92M

--79.65M

----

Notes payable and accounts payable

5.79%157.81M

2.59%159.54M

-28.74%108.93M

21.97%194.97M

-0.89%149.17M

1.96%155.51M

15.91%152.86M

18.04%159.84M

69.45%150.51M

--152.52M

-Accounts payable

5.79%157.81M

2.59%159.54M

-28.74%108.93M

21.97%194.97M

-0.89%149.17M

1.96%155.51M

15.91%152.86M

18.04%159.84M

69.45%150.51M

--152.52M

Contract liabilities

--1.92M

--1.54M

--981.76K

----

Salaries payable

46.72%59.54M

48.75%36.7M

12.61%55.96M

82.89%62.93M

74.75%40.58M

77.43%24.67M

50.17%49.69M

31.75%34.41M

25.35%23.22M

--13.91M

Taxs payable

57.80%6.44M

16.60%11.48M

114.66%12.44M

57.27%4.93M

56.35%4.08M

3.34%9.85M

39.15%5.79M

36.23%3.13M

35.60%2.61M

--9.53M

Other payable (including interest and dividends)

336.63%96.97M

108.27%51.83M

149.73%46.97M

215.63%39.85M

53.54%22.21M

31.82%24.89M

-27.71%18.81M

60.53%12.63M

123.19%14.46M

--18.88M

-Interest payable

----

--186.93K

----

-Other payable

336.63%96.97M

----

149.73%46.97M

----

53.54%22.21M

----

-27.71%18.81M

----

123.19%14.46M

----

Non current liabilities due within one year

-12.01%20.32M

-9.92%19.06M

8.01%23.05M

25.45%24.21M

27.45%23.09M

13.51%21.15M

26.73%21.34M

21.61%19.3M

37.07%18.12M

--18.64M

Total current liabilities

71.30%546.08M

130.74%544.71M

80.46%448.44M

129.74%526.8M

52.58%318.78M

10.58%236.07M

17.22%248.49M

22.26%229.31M

62.00%208.93M

--213.48M

Current liabilities

Long term deferred income

-0.05%14.56M

3.58%11.39M

10.07%12.11M

--14.43M

--14.57M

--11M

----

Lease liabilities

-33.99%39.15M

-22.79%42.67M

-23.52%48.89M

-29.90%49.84M

-7.65%59.31M

-14.36%55.26M

-9.86%63.93M

-4.19%71.1M

-10.49%64.23M

--64.53M

Total non current liabilities

546.17%477.38M

369.26%310.94M

165.99%199.32M

-9.60%64.27M

15.03%73.88M

2.68%66.26M

5.65%74.93M

-4.19%71.1M

-10.49%64.23M

--64.53M

Total liabilities

160.65%1.02B

183.01%855.65M

100.28%647.75M

96.76%591.07M

43.75%392.66M

8.75%302.33M

14.32%323.43M

14.76%300.4M

36.08%273.15M

--278.01M

Shareholders equity

Paid-in capital

1.84%415.65M

0.24%408.15M

0.98%408.15M

0.74%407.16M

12.27%404.18M

--404.18M

Capital reserve funds

6.76%3.05B

7.51%3.02B

7.14%2.95B

6.05%2.91B

4.39%2.86B

2.73%2.81B

1.05%2.76B

260.87%2.74B

266.79%2.74B

--2.73B

Retained profit

-48.86%-2.86B

-66.39%-2.74B

-78.79%-2.51B

-89.40%-2.23B

-89.22%-1.92B

-93.22%-1.65B

-109.88%-1.41B

-153.01%-1.18B

-239.89%-1.01B

---851.58M

Shareholders equity without minority interests

-54.77%609.06M

-55.65%696.59M

-51.74%848.63M

-44.98%1.08B

-36.71%1.35B

-31.29%1.57B

-28.60%1.76B

200.92%1.97B

163.33%2.13B

--2.29B

Minority interests

--12.45M

----

Total shareholder equity

-53.84%621.51M

-55.65%696.59M

-51.74%848.63M

-44.98%1.08B

-36.71%1.35B

-31.29%1.57B

-28.60%1.76B

200.92%1.97B

163.33%2.13B

--2.29B

Total liabilityies and equity

-5.42%1.64B

-17.13%1.55B

-28.12%1.5B

-26.21%1.67B

-27.56%1.74B

-26.95%1.87B

-24.18%2.08B

147.69%2.27B

138.01%2.4B

--2.56B

Currency Unit

CNY

Accounting Standards

CAS (2007)

Audit Opinions

Unqualified opinion

Auditor

PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)

	(Q6)Jun 30, 2024	(Q3)Mar 31, 2024	(FY)Dec 31, 2023	(Q9)Sep 30, 2023	(Q6)Jun 30, 2023	(Q3)Mar 31, 2023	(FY)Dec 31, 2022	(Q9)Sep 30, 2022	(Q6)Jun 30, 2022	(Q3)Mar 31, 2022
Assets
Current assets
Money funds	26.32%102.85M	11.76%95.31M	-39.02%74.2M	-46.99%69.4M	-52.42%81.42M	-63.79%85.28M	-66.59%121.67M	-46.42%130.91M	-50.48%171.13M	--235.54M
Transactional financial assets	-23.57%725.09M	-35.26%721.6M	-47.95%674M	-42.65%843.82M	-39.46%948.72M	-32.70%1.11B	-24.32%1.29B	--1.47B	--1.57B	--1.66B
Notes receivable and accounts receivable	--93.7M	--44.13M	--48.04M	--45.8M	----	----	----	----	----	--0
-Accounts receivable	--93.7M	--44.13M	--48.04M	--45.8M	----	----	----	----	----	--0
Other receivables (including interest and dividends)	-14.07%3.62M	1.53%3.4M	5.17%3.37M	14.00%3.73M	29.18%4.21M	7.42%3.35M	117.31%3.2M	119.09%3.27M	445.38%3.26M	--3.12M
-Accrued interest receivable	----	----	----	--357.87K	--266.05K	----	----	----	----	----
-Other receivable	-8.28%3.62M	----	5.17%3.37M	----	21.02%3.95M	----	117.31%3.2M	----	445.38%3.26M	----
Advance payment	-46.62%38.12M	-10.45%49.81M	25.49%53.14M	108.77%81.05M	115.98%71.41M	48.02%55.62M	50.71%42.35M	62.05%38.82M	48.21%33.06M	--37.58M
Inventories	145.83%32.61M	559.81%33.44M	363.04%23.47M	--20.09M	--13.27M	--5.07M	--5.07M	----	----	----
Other current assets	58.56%26M	363.12%31.23M	461.10%34.14M	--20.98M	--16.4M	--6.74M	--6.08M	----	----	----
Total current assets	-9.99%1.02B	-22.96%978.93M	-38.20%910.36M	-34.02%1.08B	-36.01%1.14B	-34.24%1.27B	-30.26%1.47B	491.88%1.64B	372.44%1.77B	--1.93B
Non Current assets
Fixed assets	-0.47%21.25M	----	79.09%22.1M	----	93.98%21.35M	----	-5.08%12.34M	----	-19.35%11.01M	----
Constru in process	401.75%76.51M	----	50.74%13.35M	----	73.13%15.25M	----	75.69%8.85M	----	--8.81M	----
Intangible assets	-6.15%446.29M	-6.10%454.19M	-6.11%461.98M	3.96%469.54M	3.43%475.54M	3.58%483.68M	3.61%492.02M	-6.37%451.66M	-6.25%459.75M	--466.98M
Long deferred expense	58.87%12.84M	101.99%15.1M	112.68%16.99M	20.94%10.78M	16.85%8.08M	50.10%7.48M	76.04%7.99M	250.01%8.91M	128.87%6.92M	--4.98M
Usufruct assets	-30.62%54.52M	-21.04%60.67M	-18.98%66.81M	-16.31%73.41M	-2.12%78.58M	-9.78%76.84M	-4.59%82.47M	-1.81%87.72M	-5.30%80.29M	--85.16M
Other non current assets	131.06%11.58M	-60.24%2.85M	-5.22%4.79M	-93.81%3.39M	-91.61%5.01M	-87.61%7.17M	-89.78%5.06M	7.70%54.81M	44.52%59.72M	--57.87M
Total non current assets	3.18%622.99M	-4.82%573.31M	-3.73%586.02M	-5.59%588.49M	-3.62%603.81M	-4.62%602.33M	-3.90%608.73M	-2.25%623.34M	-1.05%626.49M	--631.53M
Total assets	-5.42%1.64B	-17.13%1.55B	-28.12%1.5B	-26.21%1.67B	-27.56%1.74B	-26.95%1.87B	-24.18%2.08B	147.69%2.27B	138.01%2.4B	--2.56B
Liabilities
Current liabilities
Short term loan	154.97%203.08M	--264.55M	--200.11M	--199.92M	--79.65M	----	----	----	----	----
Notes payable and accounts payable	5.79%157.81M	2.59%159.54M	-28.74%108.93M	21.97%194.97M	-0.89%149.17M	1.96%155.51M	15.91%152.86M	18.04%159.84M	69.45%150.51M	--152.52M
-Accounts payable	5.79%157.81M	2.59%159.54M	-28.74%108.93M	21.97%194.97M	-0.89%149.17M	1.96%155.51M	15.91%152.86M	18.04%159.84M	69.45%150.51M	--152.52M
Contract liabilities	--1.92M	--1.54M	--981.76K	----	----	----	----	----	----	----
Salaries payable	46.72%59.54M	48.75%36.7M	12.61%55.96M	82.89%62.93M	74.75%40.58M	77.43%24.67M	50.17%49.69M	31.75%34.41M	25.35%23.22M	--13.91M
Taxs payable	57.80%6.44M	16.60%11.48M	114.66%12.44M	57.27%4.93M	56.35%4.08M	3.34%9.85M	39.15%5.79M	36.23%3.13M	35.60%2.61M	--9.53M
Other payable (including interest and dividends)	336.63%96.97M	108.27%51.83M	149.73%46.97M	215.63%39.85M	53.54%22.21M	31.82%24.89M	-27.71%18.81M	60.53%12.63M	123.19%14.46M	--18.88M
-Interest payable	----	----	----	--186.93K	----	----	----	----	----	----
-Other payable	336.63%96.97M	----	149.73%46.97M	----	53.54%22.21M	----	-27.71%18.81M	----	123.19%14.46M	----
Non current liabilities due within one year	-12.01%20.32M	-9.92%19.06M	8.01%23.05M	25.45%24.21M	27.45%23.09M	13.51%21.15M	26.73%21.34M	21.61%19.3M	37.07%18.12M	--18.64M
Total current liabilities	71.30%546.08M	130.74%544.71M	80.46%448.44M	129.74%526.8M	52.58%318.78M	10.58%236.07M	17.22%248.49M	22.26%229.31M	62.00%208.93M	--213.48M
Current liabilities
Long term deferred income	-0.05%14.56M	3.58%11.39M	10.07%12.11M	--14.43M	--14.57M	--11M	--11M	----	----	----
Lease liabilities	-33.99%39.15M	-22.79%42.67M	-23.52%48.89M	-29.90%49.84M	-7.65%59.31M	-14.36%55.26M	-9.86%63.93M	-4.19%71.1M	-10.49%64.23M	--64.53M
Total non current liabilities	546.17%477.38M	369.26%310.94M	165.99%199.32M	-9.60%64.27M	15.03%73.88M	2.68%66.26M	5.65%74.93M	-4.19%71.1M	-10.49%64.23M	--64.53M
Total liabilities	160.65%1.02B	183.01%855.65M	100.28%647.75M	96.76%591.07M	43.75%392.66M	8.75%302.33M	14.32%323.43M	14.76%300.4M	36.08%273.15M	--278.01M
Shareholders equity
Paid-in capital	1.84%415.65M	1.84%415.65M	0.24%408.15M	0.98%408.15M	0.98%408.15M	0.98%408.15M	0.74%407.16M	12.27%404.18M	12.27%404.18M	--404.18M
Capital reserve funds	6.76%3.05B	7.51%3.02B	7.14%2.95B	6.05%2.91B	4.39%2.86B	2.73%2.81B	1.05%2.76B	260.87%2.74B	266.79%2.74B	--2.73B
Retained profit	-48.86%-2.86B	-66.39%-2.74B	-78.79%-2.51B	-89.40%-2.23B	-89.22%-1.92B	-93.22%-1.65B	-109.88%-1.41B	-153.01%-1.18B	-239.89%-1.01B	---851.58M
Shareholders equity without minority interests	-54.77%609.06M	-55.65%696.59M	-51.74%848.63M	-44.98%1.08B	-36.71%1.35B	-31.29%1.57B	-28.60%1.76B	200.92%1.97B	163.33%2.13B	--2.29B
Minority interests	--12.45M	----	----	----	----	----	----	----	----	----
Total shareholder equity	-53.84%621.51M	-55.65%696.59M	-51.74%848.63M	-44.98%1.08B	-36.71%1.35B	-31.29%1.57B	-28.60%1.76B	200.92%1.97B	163.33%2.13B	--2.29B
Total liabilityies and equity	-5.42%1.64B	-17.13%1.55B	-28.12%1.5B	-26.21%1.67B	-27.56%1.74B	-26.95%1.87B	-24.18%2.08B	147.69%2.27B	138.01%2.4B	--2.56B
Currency Unit	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY	CNY
Accounting Standards	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)	CAS (2007)
Audit Opinions	--	--	Unqualified opinion	--	--	--	Unqualified opinion	--	--	--
Auditor	--	--	PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)	--	--	--	PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership)	--	--	--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

688192 Dizal Pharmaceutical

Dizal Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Analysis

Analyst Rating

Price Target